Home» Circulars» Opportunity For Supplying Indian Pharma Products To Yunnan Province Of China Back
 
Opportunity for supplying Indian Pharma Products to Yunnan Province of China
 

PxlNwLtrHeaderLogo


PXL/HO/Cir-105/2018-19                                                                                        Date: 19.03.2019

Hyderabad

 

 

 

Dear Sir/Madam,

 

Subject: Opportunity for supplying Indian Pharma Products to Yunnan Province of China

 

We would like to bring kind notice of the member companies that Council is in receipt of communication from our Embassy at Beijing, China stating that the Yunnan province is interested in procuring medicines from India.

 

Members are kindly aware, Pharmexcil along with Department of Commerce and Missions in China is actively pursuing the Chinese Government for fast track registration and medicines supplies from India. Towards this direction, Embassy of India at Beijing has taken up the issue of procuring Indian medicines with officials of Yunnan government authorities.

 

In a meeting between Consulate General of India in Guangzhou and Director General of Yunnan Provincial Foreign affairs in Kunming last week, the DG expressed interest of introducing Indian drugs/medicines to the city and provincial health system and requested for product list, along with any certifications like US FDA etc. that those products may have, which Indian companies can supply to Yunnan.

 

The Yunnan government is also willing to host the Indian Delegation basing on the response from India pharma companies.

 

We therefore request the member companies holding product approvals from CFDA/NMPA and interested to supply pharma products to Yunnan Province, may please share the details of the product approvals along with the company profile and any other accreditations of USFDA/EMA to regulatory@pharmexcil.com.

 

Basing on the response received from member companies, Council will communicate to the Department of Commerce and Embassy at Beijing, China for further information in this regard.

 

We look forward to receiving the details by 22nd March 2019

 

With regards,

 

 

Udaya Bhaskar

Director General